CXCL9 and neoplasm: Unexpectedly, despite an improved ICB treatment, we did not observe an increase in the CD3+ or CD8+ immune infiltration upon Cxcl9 overexpression in the tumours treated with the anti-PD-L1 antibody, which we once again reproduced in the IgG2b-treated tumours (Fig. 2e).